



Trend of OPDIVO

Sales Trend of OPDIVO by Each Cancer




Prescription Ratio in Patients Newly Treated* for 1L ESC(Squamous Cell Carcinoma)



*Patients starting treatment within the last 3 month

Source: External data (May 2022~Jan 2025: n=150~155)

Prescription Ratio in Patients Newly Treated* for 1L NSCLC



(Before approval)

*Patients starting 1L treatment within the last 1 month (Except Driver Mutation)

Source: External data (Nov 2020~Jan 2025: n=167~245)